FOLLOW US ON SOCIAL

Posted On

17
March
2022

Britain approves AstraZeneca’s antibody-based Covid therapy

Britain’s medicines regulator said on Thursday it had approved AstraZeneca’s antibody-based COVID-19 treatment for patients with poor immune response, marking a major step in the fight against the pandemic.

The decision to grant approval for the treatment was endorsed by the government’s independent expert scientific advisory body after reviewing the evidence, the Medicines and Healthcare products Regulatory Agency (MHRA) said.

Vaccines continue to be the first line of defence, but “we know that some people may not respond adequately to these vaccines and for a small number of individuals Covid-19 vaccines may not be recommended”, June Raine, the agency’s chief executive, said on Thursday. “For these people, Evusheld could provide effective protection.”

AstraZeneca’s antibody cocktail, branded Evusheld, has already been authorized in the United States to prevent COVID-19 infections in individuals with weak immune systems or a history of severe side effects from coronavirus vaccines. 

RelatedPost

Related Blog post

UserComment

Valuable Users idea's
0 Comments

Leave a Reply

Your email address will not be published.